#Japan #Tokyo #CRO #Alfresa #ArkMS

ArkMS to Become a Consolidated Subsidiary

In a strategic move, Alfresa Holdings has announced that ArkMS, a non-consolidated subsidiary engaged in Contract Research Organization (CRO) operations, will officially transition to a consolidated subsidiary. This change, effective from April 1, 2026, is part of the company’s broader growth strategy centered around enhancing its total supply chain service (TSCS) capabilities for pharmaceuticals.

Background of the Transition

Alfresa Group has been executing a growth strategy under its long-term vision leading up to the fiscal year 2032. With the aim of ensuring a comprehensive approach to pharmaceutical development, manufacturing, logistics, and sales, the Group is focusing on integrating these processes into a cohesive service framework.

The acquisition of all shares of ArkMS, which was established through a company split from Intage Healthcare, will bolster Alfresa’s position in the CRO sector. By integrating ArkMS into the consolidated financial reporting, Alfresa acknowledges the increased importance of ArkMS's contributions towards the development and support of drugs across the supply chain.

As part of the 2027 first quarter financial reporting, ArkMS will officially be listed as a consolidated subsidiary. The move emphasizes the growing role of ArkMS in supporting the TSCS, linking drug development with post-marketing surveillance (PMS) and ensuring safe and effective product delivery to market.

Management Structure as of April 2026

As the newly consolidated entity, ArkMS will benefit from a structured management approach, directly reporting to the CEO, Akira Mizuho. The organizational framework will include departments dedicated to business strategy, medical solutions, clinical research, risk management (RM), management planning, human resources, and internal audit. Each of these departments will play a pivotal role in ArkMS's operations, strategically aligning with the objectives of the Alfresa Group.

Key Personnel

• - CEO: Akira Mizuho, with a solid background in pharmaceutical and clinical research leadership. Having joined ArkMS in 2007, he has climbed through management ranks and now leads the company with a vision that matches Alfresa’s goals.
• - Board of Directors: The board, responsible for strategic decision-making, includes other experienced executives, such as Tomokazu Yahagi, Ryota Kubo, and Soichi Nemoto, all of whom bring diverse expertise from different sectors within the pharmaceutical industry.
• - Department Heads: The heads of various departments will oversee specific operational facets, ensuring that ArkMS meets its objectives in supporting drug development while adhering to industry standards and practices.

Conclusion

The transition of ArkMS into a consolidated subsidiary marks a significant step in Alfresa's overarching strategy to refine and enhance its pharmaceutical service offerings. This structural change is anticipated to streamline operations and drive growth, positioning the group to excel in a competitive landscape, while delivering critical solutions in medicine and healthcare. As the integration unfolds, stakeholders will be keenly observing the impacts on research capabilities, supply chain efficiency, and overall responsiveness to market needs.